Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition

15.07.25 15:00 Uhr

Werte in diesem Artikel

Technology-enabled research approach and AI-powered analysis identify unmet needs in patients with congenital adrenal hyperplasia

SAN FRANCISCO, July 15, 2025 /PRNewswire/ -- PicnicHealth, a health technology company dedicated to advancing the next generation of non-interventional research, today announced its research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX), the CAHtalog® Registry, identified an unmet need in patients with classic congenital adrenal hyperplasia (CAH). Using PicnicHealth's AI-powered technology to curate medical records and enable remote participation, the study revealed that CAH patients require lifelong, continuous adjustments to glucocorticoid dosing—the current standard treatment—to maintain condition control.

PicnicHealth is a leading health technology company dedicated to simplifying healthcare for everyone. (PRNewsfoto/PicnicHealth)

CAHtalog® was founded in 2021 by PicnicHealth and Neurocrine, in collaboration with the CARES Foundation, to establish a U.S.-based registry that helps patients with CAH by advancing patient-centered research and enhancing the scientific community's foundational knowledge of the condition. CAH is a rare genetic condition that affects adrenal gland function, disrupting hormone production and impacting growth and development. Conducting longitudinal studies on rare diseases is challenging for researchers using site-based models due to the wide geographic spread of patients. Tech-enabled research models improve access and participation by removing the burden of in-person visits over extended periods.

"This study shows how researchers can minimize patient burden while still gathering valuable, long-term insights to answer their research questions," says Dan Drozd, MD, MSc, chief medical officer at PicnicHealth. "New technologies, including AI, make it possible to integrate data from across patients' medical records, expanding knowledge on this condition and providing direct benefits to participating patients."

PicnicHealth conducts non-interventional research by collecting medical records from anywhere patients receive care and enabling patients to complete research activities through an intuitive app. The app also features an AI assistant that empowers patients to navigate their medical records with ease. This novel approach to registries helps life sciences companies answer their research questions more efficiently while fostering long-term patient engagement. The CARES Foundation proved crucial for successfully recruiting and engaging CAH patients in the study.

"We're always looking for new ways to support our patients," says Dina Matos, executive director of the CARES Foundation. "This registry gives our community the opportunity to contribute their valuable data to advance CAH research, while also empowering them with tools to better manage their condition throughout their health journey."

In addition to this key finding on glucocorticoid dosing, additional results from the CAHtalog® registry on treatment patterns and condition progression were presented earlier this week at ENDO 2025 in Treatment Patterns and Changes in Health States in Patients with Classic Congenital Adrenal Hyperplasia: An Analysis of Data from the CAHtalog® Registry and in the poster ADRENAL (EXCLUDING MINERALOCORTICOIDS): Adrenal Insufficiency and CAH III.

Patients interested in joining the CAHtalog® registry and advancing critical insights like these can learn more here.

CAHtalog® is a registered trademark of Neurocrine Biosciences, Inc.

About PicnicHealth
PicnicHealth is a leading health technology company dedicated to advancing the next generation of non-interventional research. To date, the company's direct-to-patient approach and innovative AI and technology platform have enabled 12 of the top 20 largest life science companies to run more efficient non-interventional research. PicnicHealth has given tens of thousands of patients access to tools and virtual care services to simplify their care journey. PicnicHealth was recently named one of the World's Best Digital Health Companies by Newsweek, "Best MedTech Startup" by MedTech Breakthrough, and "Best AI-enabled Life Sciences Solution" by Global Health & Pharma. The future is here with PicnicHealth. To learn more, visit picnichealth.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-leverages-picnichealth-to-reveal-critical-care-gaps-for-patients-with-rare-genetic-condition-302505107.html

SOURCE PicnicHealth

In eigener Sache

Übrigens: Neurocrine Biosciences und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Neurocrine Biosciences

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Neurocrine Biosciences

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Neurocrine Biosciences Inc.

Wer­bung

Analysen zu Neurocrine Biosciences Inc.

DatumRatingAnalyst
16.07.2019Neurocrine Biosciences OutperformOppenheimer & Co. Inc.
21.11.2018Neurocrine Biosciences BuyCanaccord Adams
07.08.2018Neurocrine Biosciences BuyStifel, Nicolaus & Co., Inc.
22.02.2018Neurocrine Biosciences BuyNeedham & Company, LLC
02.11.2017Neurocrine Biosciences BuyH.C. Wainwright & Co.
DatumRatingAnalyst
16.07.2019Neurocrine Biosciences OutperformOppenheimer & Co. Inc.
21.11.2018Neurocrine Biosciences BuyCanaccord Adams
07.08.2018Neurocrine Biosciences BuyStifel, Nicolaus & Co., Inc.
22.02.2018Neurocrine Biosciences BuyNeedham & Company, LLC
02.11.2017Neurocrine Biosciences BuyH.C. Wainwright & Co.
DatumRatingAnalyst
14.12.2007Neurocrine Biosciences DowngradeBear Stearns Companies Inc.
14.12.2007Neurocrine Biosciences DowngradePiper Jaffray & Co.
14.12.2007Neurocrine Biosciences neues KurszielJefferies & Company Inc.
29.06.2006Neurocrine Biosciences neues KurszielUBS
23.06.2006Neurocrine Bio. neues KurszielMorgan Stanley

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Neurocrine Biosciences Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen